Monashee Investment Management LLC Chinook Therapeutics, Inc. Transaction History

Monashee Investment Management LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 01, 2022	SELL	$17.51 - $23.37 $2.54 Million - $3.39 Million	-145,000 Reduced 60.42%	95,000 $1.87 Million
Q2 2022 Aug 12, 2022	BUY	$12.59 - $18.8 $1.89 Million - $2.82 Million	150,000 Added 166.67%	240,000 $4.2 Million
Q1 2022 May 12, 2022	SELL	$12.02 - $16.69 $60,100 - $83,450	-5,000 Reduced 5.26%	90,000 $1.47 Million
Q4 2021 Feb 07, 2022	BUY	$10.69 - $16.83 $1.02 Million - $1.6 Million	95,000 New	95,000 $1.55 Million
Q1 2021 May 14, 2021	SELL	$14.17 - $19.11 $3.87 Million - $5.22 Million	-272,949 Closed	0 $0
Q4 2020 Feb 11, 2021	BUY	$11.9 - $20.91 $3.25 Million - $5.71 Million	272,949 New	272,949 $4.33 Million

234K

Ticker KDNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,896,300
Description
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. ...

Get notified when there are updates to the investment portfolio of Monashee Investment Management LLC, based on Form 13F filings with the SEC.

Stay updated on Monashee Investment Management LLC with notifications on news.